+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-01-12Number of Pages: 188

Hemophilia Treatment Drugs Market (Product - Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Desmopressin, and Antifibrinolytic Agents; Disease Indication - Hemophilia A, Hemophilia B, Acquired Hemophilia, and Hemophilia C; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024

Global Hemophilia Treatment Drugs Market: Overview

The global hemophilia treatment drugs market is presently catering to various sub-types of hemophilia such as hemophilia A, hemophilia B and others such as acquired hemophilia and hemophilia C. The increasing awareness of this disorder and the introduction of innovative ways of managing this disease has opened up several opportunities for the global market in recent years. According to the research report, the global hemophilia treatment drugs market was valued at US$15.8 bn in 2015 and is expected to reach US$25.1 bn in 2024, as the market is projected to progress at a CAGR of 5.4%.

The global market is also estimated to benefit from the several blockbuster drugs in the existing portfolio. Presently, these drugs are contributing to the major share of the revenue of the market. The introduction of new drugs and FDA approvals for clinical trials to launch blockbuster treatments is expected to drive this market in the coming years. The commercial availability of promising drugs is anticipated to change the way hemophilia is managed and treated for many patients during the forecast period.

hemophilia treatment drugs market

Recombinant Coagulation Factor Concentrates Lead Global Market due to Low Risk of Blood-borne Infections

On the basis of product, the global market is segmented into recombinant coagulation factor concentrates, desmopressin, plasma derived coagulation factor concentrates, and antifibrinolytic agents. Out of these products, the recombinant coagulation factor concentrates are expected to dominate the global market in the coming years. The growing preference of medical practitioners for these therapies due to low risk of blood borne infections is anticipated to drive this segment. In 2015, the recombinant coagulation factor concentrates segment held a share of 46.6% in the global market in terms of revenue. This segment is further divided into factor VIII, factor IX and combination drugs.

North America to Show Sustained Demand as Awareness about Disease Continues to Grow

In terms of geography, the global hemophilia treatment drugs market is categorized into Europe, Asia Pacific, North America, Latin America, and the Middle East and Africa. Out of these regions, North America has been leading the global market for a few decades and is expected to continue its stance in the coming years due to well-established healthcare infrastructure. Furthermore, the growing awareness about the disease in the region is also expected to boost sales of products in the coming years.  Currently, the U.S. is leading the hemophilia drugs market in North America.

On the other hand, Europe is anticipated to lose its share as several top-selling drug brands are experiencing patent cliff. Presently, the U.K is leading the Europe market. Asia Pacific is also anticipated to offer several lucrative opportunities to the overall market due to an exponentially growing demand for unmet medical needs. The rising per capita income, improving healthcare facilities, growing awareness about the disorder, and emerging economies of Asia Pacific have lent a significant impetus to the overall market. Additionally, increasing focus on treating bleeding disorders across Asia Pacific and Latin America are also expected give the overall market a remarkable boost in the coming few years.

Some of the key players operating in the global hemophilia treatment drugs market are Shire Plc, Biogen, Pfizer Inc., Novo Nordisk A/S, CSL Behring, F. Hoffmann-La Roche Ltd., Bayer AG, Biotest AG, Kedrion Biopharma Inc., and Octapharma AG. The competitive landscape of the global market can be described as a consolidated one with top ten players holding a mammoth share in the overall market in terms of revenue. Over the coming years, these companies are expected to show a keen interest in expanding their geographical reach and widening their presence in various parts of the world.

Global Hemophilia Treatment Drugs Market: Overview

Hemophilia is a rare blood disorder. Hemophilia is a combination of two Greek words that is haima (blood) and philia (affection). Hemophilia is a hereditary disorder, passed from parents to the child. Hemophilia is a bleeding disorder which causes excess bleeding and poor blood clotting. The people with hemophilia are generally known as hemophiliacs. There are two main type of hemophilia, hemophilia A and hemophilia B. Hemophilia A or classical hemophilia is the most common type of hemophilia, caused by lack of factor VIII in blood. Hemophilia B also known as Christmas disease, as it was firstly diagnosed in person named Steven Christmas. Hemophilia B is caused by lack of factor IX in blood. Other hemophilia are hemophilia C, Acquired Hemophilia etc. Hemophilia A & B is passed from mother to child, but hemophilia C is passed from both mother and father to child. This report analyzes the current and future prospects of the hemophilia treatment drugs market based on type of product, disease indication, distribution channel and geography.

Global Hemophilia Treatment Drugs Market: Research Methodology

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major radiography techniques in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for each Product type, disease indication, distribution channel, and geography for the period 2015 to 2024, considering the macro and micro environmental factors. The revenue generated from each product was calculated by considering number of products used in the procedures and their market demand as per their use, number of product launched, average cost of products of each sub segment, trends in industry, end user trend, and adoption rate across all the geographies. The revenue generated for disease indication was calculated on the basis of prevalence of diseases in humans.

Global Hemophilia Treatment Drugs Market: Scope

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on type of product, disease indication, distribution channel and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influence the hemophilia treatment drugs market in the current and future scenario. The report also provides value chain analysis of the market that describes the sequence of activities involved from manufacturing to their final reach to the end users.

Global Hemophilia Treatment Drugs Market: Regional Outlook

Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the market. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for countries of North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Key Players Mentioned in the Report are:

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the hemophilia treatment drugs market report are Novo Nordisk A/S, CSL Behring, F. Hoffmann-La Roche Ltd., Bayer AG, Pfizer Inc., Biotest AG, Kedrion Pharma, Inc., Octapharma AG, Shire Plc,  Biogen and some other players who are involved in the hemophilia treatment drugs market.

The global hemophilia treatment drugs market is segmented as follows:

Global Hemophilia Treatment Drugs Market Revenue, by Product type

  • Recombinant coagulation factor concentrates
    • Factor VIII
    • Factor IX
    • Combination
  • Plasma derived coagulation factor concentrates
    • Factor VIII
    • Factor IX
    • Combination
  • Desmopressin
  • Antifibrinolytic agents

Global Hemophilia Treatment Drugs Market Revenue, by Disease Indication

  • Hemophilia A
  • Hemophilia B
  • Others

Global Hemophilia Treatment Drugs Market Revenue, by Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-commerce

Global Hemophilia Treatment Drugs Market Revenue, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • U.K.
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa


 
 
Back To Top